



New York State Medicaid Drug Utilization Review (DUR) Board Meeting

The DUR Board will meet on November 10, 2022, from 10:00 am to 2:00 pm
Meeting Room 2, Concourse Level, Empire State Plaza, Albany NY

This meeting will also be available for public viewing from the:

University at Buffalo School of Pharmacy and Pharmaceutical Sciences
Abbott Hall - Room 130, Buffalo, NY 14264

SUNY Global Center
116 East 55th Street, New York, NY 10022

Live and Archived Webcast - [Department of Health Events and Webcasts](#)

Agenda Items

A. Drug Utilization Review

The DUR Board will review the following drugs and, if applicable, recommend clinical criteria and/or interventions to ensure appropriate drug utilization:

1. Risdiplam (Evrysdi®)
2. Nusinersen (Spinraza®)
3. Ocrelizumab (Ocrevus®)
4. Betibeglogene autotemcel (Zynteglo®)

B. Pharmacy Program Updates

The DUR Board will be provided updates on the following topics:

1. Medicaid Prescriber Education Program - [MPEP](#)
2. Hepatitis C Virus – Utilization of Direct Acting Antivirals - [FFS PDP](#)

Agenda Timeline (subject to change based on meeting proceedings)

10:00 – 10:15	Welcome, Introductions and Opening Comments
10:15 – 11:15	Public Comment Period
11:15 – 1:15	Drug Utilization Reviews

1:15 – 1:45	Pharmacy Program Updates
1:45 – 2:00	Closing Comments and Adjournment

Interested parties must submit a request to provide public comment during the DUR Board meeting and must complete the registration process by November 2, 2022. Requests to provide public comment may be made by calling 518-486-3209 or emailing dur@health.ny.gov (please reference DUR Board Meeting Speaker Request).

Public comments are limited to items on the agenda. Comments must be brief (2 minutes) and the total comment period will not exceed sixty (60) minutes. The Department of Health (DOH) reserves the right to limit the number of interested parties providing public comment in order to meet agenda timelines and accomplish meeting objectives.

All written statements must be received in an electronic format by November 2, 2022. Written statements should summarize key points and may not exceed two (2) pages in length. Any studies cited should be referenced, with the primary source of funding included.

Clinical information must be submitted in an electronic format by October 26, 2022, or the DUR Board may not have ample time to review the information.

All information must be sent to the DOH. Interested parties should not contact or send any information directly to DUR Board members.